Drug intelligence / Profile preview

sotetsuflavone

Development stage
Preclinical
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01

Overview

Sotetsuflavone is a naturally occurring biflavonoid compound isolated from plants such as Cycas revoluta and Taxus cuspidata. It exhibits notable anti-cancer properties in preclinical studies. Mechanistically, sotetsuflavone inhibits proliferation, migration, and invasion of non-small cell lung cancer (NSCLC) cells by inducing apoptosis (via upregulation of cytochrome C, cleaved-caspase 3/9 and Bax; downregulation of Bcl-2), causing G0/G1 cell cycle arrest (by reducing cyclin D1 and CDK4), and promoting autophagy through inhibition of the PI3K/Akt/mTOR signaling pathway. Additionally, it is a potent inhibitor of Dengue virus NS5 RNA-dependent RNA polymerase with an IC50 value around 0.16 μM[2][4][5]. Sotetsuflavone has not been approved for clinical use but shows promise as an anti-tumor agent in preclinical models.

Other names
8-[5-(5,7-dihydroxy-4-oxo-chromen-2-yl)-2-hydroxyphenyl]-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-chromen-4-one2608-21-1Sotetsuflavon
02

Targets

PI3K (Phosphoinositide-3-kinase regulatory subunit 6)mTOR (Mammalian target of rapamycin kinase)RdRp (Coronavirus RNA-dependent RNA polymerase)AKT (RAC-alpha serine/threonine-protein kinase)

Beyond the preview

Go deeper on sotetsuflavone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sotetsuflavone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call